← Leaderboards
James E Galvin
Weill Medical Coll Of Cornell Univ
$66,836,874
Attributed
$116,593,907
Total exposure
19
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $30.5M · FY2010–25$50M$37.5M$25M$12.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$131,970,124 · 21
By mechanism
R01$92,962,861 · 8
P01$11,821,621 · 1
RF1$10,293,481 · 1
P30$7,086,765 · 6
U01$3,640,661 · 1
R56$3,171,435 · 1
Top collaborators
- Dedra S Buchwald6 shared
- Craig Stephen Atwood5 shared
- Zina Ben-Miled5 shared
- Malaz Boustani5 shared
- Tracy A. Butler5 shared
- John Alam4 shared
- John Sai Keong Kauwe4 shared
- Spero M Manson4 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Ekta Khurana$4,892,615
- P.j. Klasse$9,373,615
- Joshua Levitz$10,823,962
- Crina M Nimigean$11,566,137
- Bruce D McCandliss$4,364,225
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseDementiaCognitiveCommunitiesImpaired CognitionDiagnosisBiological MarkersDetectionS Disease Related DementiaElderlyUniversitiesPersonsMild Cognitive ImpairmentSocialClinical TrialsFundingParticipantInnovationProgramsCognitionAffectSamplingEarly Diagnosis
Grant awards (74)
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)$6,072,987
R01 · FY2025 · AG
FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.$5,308,961
R01 · FY2025 · AG
Alzheimer's Disease and Related Dementias (ADRD) prevalence in American Samoa$4,106,948
RF1 · FY2025 · AG
Multicultural Community Dementia Screening$2,541,385
R01 · FY2025 · AG · contact PI
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)$1,849,047
U01 · FY2025 · AG
Cross-disciplinary research opportunity for training in AD/ADRD science (CROSSROADS)$558,735
T32 · FY2025 · AG
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)$8,066,994
R01 · FY2024 · AG
Natives Engaged in Alzheimer's Research$2,898,840
P01 · FY2024 · AG
Multicultural Community Dementia Screening$2,627,226
R01 · FY2024 · AG · contact PI
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)$1,791,614
U01 · FY2024 · AG
The LUCINDA Trial$1,365,893
R01 · FY2024 · AG
Digital Detection of Dementia Studies (D cubed Studies).$939,271
R01 · FY2024 · AG
Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)$661,911
P30 · FY2024 · AG · contact PI
Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)$516,374
P30 · FY2024 · AG · contact PI
Cross-disciplinary research opportunity for training in AD/ADRD science (CROSSROADS)$277,669
T32 · FY2024 · AG
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)$250,000
R01 · FY2024 · AG
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$8,479,107
R01 · FY2023 · AG
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)$6,682,055
R01 · FY2023 · AG
Natives Engaged in Alzheimer's Research$2,934,616
P01 · FY2023 · AG
Multicultural Community Dementia Screening$2,687,896
R01 · FY2023 · AG · contact PI
Reducing Disparities in Dementia and VCID Outcomes in a Multicultural Rural Population$1,143,639
R01 · FY2023 · NS · contact PI
Digital Detection of Dementia Studies (D cubed Studies).$878,191
R01 · FY2023 · AG
Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)$693,698
P30 · FY2023 · AG · contact PI
Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)$556,220
P30 · FY2023 · AG · contact PI
Multicultural Community Dementia Screening$227,366
R01 · FY2023 · AG · contact PI
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$10,254,288
R01 · FY2022 · AG
Alzheimer's Disease and Related Dementias (ADRD) prevalence in American Samoa$6,186,533
RF1 · FY2022 · AG
Deep Phenotypic Characterization of Prodromal Dementia with Lewy Bodies$3,171,435
R56 · FY2022 · AG · contact PI
Natives Engaged in Alzheimer's Research$2,938,224
P01 · FY2022 · AG
Multicultural Community Dementia Screening$2,713,214
R01 · FY2022 · AG · contact PI
Reducing Disparities in Dementia and VCID Outcomes in a Multicultural Rural Population$2,165,588
R01 · FY2022 · NS · contact PI
The LUCINDA Trial$1,366,388
R01 · FY2022 · AG
Digital Detection of Dementia Studies (D cubed Studies).$900,884
R01 · FY2022 · AG
Native Alzheimer's Disease Resource Center for Minority Aging Research (NAD-RCMAR)$539,436
P30 · FY2022 · AG
Multicultural Community Dementia Screening$253,874
R01 · FY2022 · AG · contact PI
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$10,764,669
R01 · FY2021 · AG
Natives Engaged in Alzheimer's Research$3,049,941
P01 · FY2021 · AG
Multicultural Community Dementia Screening$2,746,242
R01 · FY2021 · AG · contact PI
The LUCINDA Trial$1,413,113
R01 · FY2021 · AG
Reducing Disparities in Dementia and VCID Outcomes in a Multicultural Rural Population$1,143,639
R01 · FY2021 · NS · contact PI
Digital Detection of Dementia Studies (D cubed Studies).$1,048,978
R01 · FY2021 · AG
Reducing Disparities in Dementia and VCID Outcomes in a Multicultural Rural Population$1,031,346
R01 · FY2021 · NS · contact PI
Native Alzheimer's Disease Resource Center for Minority Aging Research (NAD-RCMAR)$548,322
P30 · FY2021 · AG
Reducing Disparities in Dementia and VCID Outcomes in a Multicultural Rural Population$1,253,021
R01 · FY2020 · NS · contact PI
Digital Detection of Dementia Studies (D cubed Studies).$1,094,329
R01 · FY2020 · AG
Native Alzheimer's Disease Resource Center for Minority Aging Research (NAD-RCMAR)$549,629
P30 · FY2020 · AG
The LUCINDA Trial$1,463,084
R01 · FY2019 · AG
Reducing Disparities in Dementia and VCID Outcomes in a Multicultural Rural Population$1,278,045
R01 · FY2019 · NS · contact PI
Native Alzheimer's Disease Resource Center for Minority Aging Research (NAD-RCMAR)$561,600
P30 · FY2019 · AG
The LUCINDA Trial$1,603,736
R01 · FY2018 · AG
Multicultural Community Dementia Screening$477,428
R01 · FY2018 · AG · contact PI
Core B. Clinical Core$452,214
P30 · FY2018 · AG · contact PI
Outreach, Recruitment and Education Core$157,821
P30 · FY2018 · AG · contact PI
Core B. Clinical Core$452,214
P30 · FY2017 · AG · contact PI
Outreach, Recruitment and Education Core$157,821
P30 · FY2017 · AG · contact PI
Multicultural Community Dementia Screening$477,428
R01 · FY2015 · AG · contact PI
Core B. Clinical Core$452,214
P30 · FY2015 · AG · contact PI
Outreach, Recruitment and Education Core$157,821
P30 · FY2015 · AG · contact PI
Multicultural Community Dementia Screening.$79,054
R01 · FY2015 · AG · contact PI
CLINICAL CORE (AND SMP)$546,676
P30 · FY2014 · AG · contact PI
Multicultural Community Dementia Screening.$530,849
R01 · FY2014 · AG · contact PI
EDUCATION AND INFORMATION TRANSFER CORE$350,845
P50 · FY2014 · AG · contact PI
NEUROPATHOLOGY CORE$82,794
P30 · FY2014 · AG · contact PI
Multicultural Community Dementia Screening$42,233
R01 · FY2014 · AG · contact PI
Multicultural Community Dementia Screening.$501,671
R01 · FY2013 · AG · contact PI
EDUCATION AND INFORMATION TRANSFER CORE$327,084
P50 · FY2013 · AG · contact PI
Multicultural Community Dementia Screening.$530,886
R01 · FY2012 · AG · contact PI
EDUCATION AND INFORMATION TRANSFER CORE$337,701
P50 · FY2012 · AG · contact PI
Multicultural Community Dementia Screening.$557,903
R01 · FY2011 · AG · contact PI
EDUCATION AND INFORMATION TRANSFER CORE$338,592
P50 · FY2011 · AG · contact PI
EDUCATION AND INFORMATION TRANSFER CORE$347,136
P50 · FY2010 · AG · contact PI
Dementia of Parkinson Type: Clinicopathologic Phenotype$151,686
K08 · FY2004 · AG
Dementia of Parkinson Type: Clinicopathologic Phenotype$151,686
K08 · FY2003 · AG
Dementia of Parkinson Type: Clinicopathologic Phenotype$152,166
K08 · FY2002 · AG